טוען...
Selective mTORC2 inhibitor therapeutically blocks breast cancer cell growth and survival
Small molecule inhibitors of the mTORC2 kinase (torkinibs) have shown efficacy in early clinical trials. However, the torkinibs under study also inhibit the other mTOR-containing complex mTORC1. While mTORC1/mTORC2 combined inhibition may be beneficial in cancer cells, recent reports describe compen...
שמור ב:
| הוצא לאור ב: | Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5882532/ https://ncbi.nlm.nih.gov/pubmed/29358172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-17-2388 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|